Drug Type Biosimilar, Monoclonal antibody |
Synonyms Adalimumab biosimilar (Samsung Bioepis), adalimumab-bwwd, SB-5 + [3] |
Target |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date EU (24 Aug 2017), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Polyarticular Juvenile Idiopathic Arthritis | US | 28 Jun 2024 | |
Enteritis | KR | 20 Sep 2017 | |
Spondylometaphyseal Dysplasia, Axial | KR | 20 Sep 2017 | |
Ankylosing Spondylitis | EU | 24 Aug 2017 | |
Ankylosing Spondylitis | IS | 24 Aug 2017 | |
Ankylosing Spondylitis | LI | 24 Aug 2017 | |
Ankylosing Spondylitis | NO | 24 Aug 2017 | |
Arthritis, Psoriatic | EU | 24 Aug 2017 | |
Arthritis, Psoriatic | IS | 24 Aug 2017 | |
Arthritis, Psoriatic | LI | 24 Aug 2017 | |
Arthritis, Psoriatic | NO | 24 Aug 2017 | |
Axial Spondyloarthritis | EU | 24 Aug 2017 | |
Axial Spondyloarthritis | IS | 24 Aug 2017 | |
Axial Spondyloarthritis | LI | 24 Aug 2017 | |
Axial Spondyloarthritis | NO | 24 Aug 2017 | |
Chronic large plaque psoriasis | EU | 24 Aug 2017 | |
Chronic large plaque psoriasis | IS | 24 Aug 2017 | |
Chronic large plaque psoriasis | LI | 24 Aug 2017 | |
Chronic large plaque psoriasis | NO | 24 Aug 2017 | |
Colitis, Ulcerative | EU | 24 Aug 2017 |
Not Applicable | - | uhuwysntwj(pzjdkxslbb) = Common reasons for SB5 discontinuation were inefficacy (10.6%) and adverse events (9.9%) rcmndyulxo (riszljliit ) View more | Positive | 07 Sep 2022 | |||
Not Applicable | 1,000 | jxumetgtzm(gfzoilfbqb) = lviuxeavyd dyxpkrtasq (vvfvgepbog, 11.4) View more | - | 01 Jun 2022 | |||
Phase 1 | - | 188 | SB5-HC (40 mg/0.4 mL) | gekjvetwik(tdscqavpbf) = izkpysiiro cktqxgvqoz (jkjiuqeakh, 0.9200.8262 - 1.0239) View more | - | 01 Jun 2022 | |
SB5-LC (40 mg/0.8 mL) | gekjvetwik(tdscqavpbf) = uqspgirxxf cktqxgvqoz (jkjiuqeakh, 0.9840.9126 - 1.0604) View more | ||||||
Phase 1 | - | 190 | (Pen of SB5) | ogilwljrll(zfnbrlzvwl) = lhgguwkvab otlhxhwrlb (mcqsrpgsuu, hbxgguddqe - ipbiykphrx) View more | - | 18 Mar 2019 | |
(PFS of SB5) | ogilwljrll(zfnbrlzvwl) = xihmqsthdh otlhxhwrlb (mcqsrpgsuu, sxwkrmuslf - iuytflvnxk) View more | ||||||
Phase 1 | - | 95 | (delivered subcutaneously via AI) | wuvbgdrduy(uhxtshkfpe) = For the primary endpoints, the 90% CIs for the ratio of geometric least squares means for SB5 AI to SB5 PFS ranged between 0.9503 and 1.2240, which were all within the equivalence margin of 0.80-1.25 egvfuponle (rcenmelelt ) | Negative | 05 Nov 2018 | |
(delivered subcutaneously PFS) | |||||||
Phase 1 | - | 189 | (EU Sourced Humira®) | ugtafnupys(gfmslztagi) = vykyterldl aybsiqjdcb (xlyzqxwcrv, dhwrsdrlhl - riuvhwxqxr) View more | - | 21 Sep 2018 | |
(US Sourced Humira®) | ugtafnupys(gfmslztagi) = xsrysakyin aybsiqjdcb (xlyzqxwcrv, gynjkpmkcd - knmhmtkyyn) View more | ||||||
Phase 3 | - | - | aaachufjxw(gfsqzzvvob) = jyhrqexcoe upvkcfhkss (szpqvvcimv ) | - | 14 Jun 2017 | ||
Reference Adalimumab (ADL) | aaachufjxw(gfsqzzvvob) = pgirkhayvy upvkcfhkss (szpqvvcimv ) | ||||||
Phase 3 | 544 | (SB5 (Proposed Biosimilar to Adalimumab)) | ezngjpnlda(ixujusyrre) = jrnlpciwgn safddxrnvr (bpydysdjpu, crwggvmlwn - msdioimxct) View more | - | 19 Jan 2017 | ||
(Humira (Adalimumab)) | ezngjpnlda(ixujusyrre) = ifxdtsvzwf safddxrnvr (bpydysdjpu, nmilylabbi - pjlugecomk) View more | ||||||
Phase 1 | - | 189 | itkqucoklg(wwjduppgem) = ifgvjoourt ieaxfcdrpp (qhtvzyznwj, 0.885 - 1.108) View more | Positive | 10 Jun 2015 | ||
EU-ADL | itkqucoklg(wwjduppgem) = agbhwcvqws ieaxfcdrpp (qhtvzyznwj, 0.904 - 1.131) View more |